Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials

Background: Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-1 monotherapy failed to provide benefit in phase-III trials. Success of ICI depends on the presenc...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Joanne M. Mankor, Maria J. Disselhorst, Myrthe Poncin, Paul Baas, Joachim G.J.V. Aerts, Heleen Vroman
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2020-12-01
Serie:	EBioMedicine
Ämnen:	Malignant pleural mesothelioma Immune checkpoint inhibitors Immunotherapy Immune monitoring Nivolumab Ipilimumab
Länkar:	http://www.sciencedirect.com/science/article/pii/S2352396420304163
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!